サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1149311

月経前症候群治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Premenstrual Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 144 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
月経前症候群治療市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年09月29日
発行: Transparency Market Research
ページ情報: 英文 144 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の月経前症候群治療市場について調査し、市場の概要とともに、2022年～2031年の予測、薬剤タイプ別、流通チャネル別、電気自動車タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の月経前症候群治療市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の月経前症候群治療市場の分析と予測、2017年～2031年

第5章 主な洞察

第6章 世界の月経前症候群治療市場の分析と予測、薬剤タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測、薬剤タイプ別、2017年～2031年
  • 薬剤タイプ別の市場の魅力

第7章 世界の月経前症候群治療市場の分析と予測、流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測、流通チャネル別、2017年～2031年
  • 流通チャネル別の市場の魅力

第8章 世界の月経前症候群治療市場の分析と予測、地域別

  • 主な調査結果
  • 市場価値予測、地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別の市場の魅力

第9章 北米の月経前症候群治療市場の分析と予測

第10章 欧州の月経前症候群治療市場の分析と予測

第11章 アジア太平洋の月経前症候群治療市場の分析と予測

第12章 ラテンアメリカの月経前症候群治療市場の分析と予測

第13章 中東・アフリカの月経前症候群治療市場の分析と予測

第14章 競合情勢

  • 市場参入企業-競合マトリックス（層と企業規模別）
  • 市場シェア分析、企業別（2021年）
  • 企業プロファイル
    • Allergan（AbbVie, Inc.）
    • Bayer AG
    • Fresenius Kabi AG
    • Johnson &Johnson Services, Inc.
    • Lilly
    • Mylan NV（Viatris, Inc.）
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd
図表

List of Tables

  • Table 01: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 05: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 08: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 17: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 02: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 03: Global Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 04: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Antidepressants, 2017-2031
  • Figure 05: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Diuretics, 2017-2031
  • Figure 06: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Pain Relievers, 2017-2031
  • Figure 07: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Oral Contraceptives & Ovarian Suppression Agents, 2017-2031
  • Figure 08: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 09: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 10: Global Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 11: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 12: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by E-commerce, 2017-2031
  • Figure 13: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Other, 2017-2031
  • Figure 14: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 15: Global Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 16: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 17: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 18: North America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 19: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 20: North America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 21: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 22: North America Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 23: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 24: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 25: Europe Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 26: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 27: Europe Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 28: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 29: Europe Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 31: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 32: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 33: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 34: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 36: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 37: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 38: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 39: Latin America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 40: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Latin America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 43: Latin America Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 44: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 45: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
  • Figure 46: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022-2031
  • Figure 47: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 48: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022-2031
  • Figure 49: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 50: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022-2031
目次
Product Code: TMRGL2922

The report provides revenue of the global premenstrual syndrome treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global premenstrual syndrome treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the premenstrual syndrome treatment market.

The report delves into the competitive landscape of the global premenstrual syndrome treatment market. Key players operating in the global premenstrual syndrome treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global premenstrual syndrome treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Premenstrual Syndrome Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence North America & Europe with Key Countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 6.3.1. Antidepressants
    • 6.3.2. Diuretics
    • 6.3.3. Pain Relievers
    • 6.3.4. Oral Contraceptives & Ovarian Suppression Agents
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug Type

7. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 7.3.1. Retail Pharmacies
    • 7.3.2. E-commerce
    • 7.3.3. Others
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Premenstrual Syndrome Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug Type, 2017 - 2031
    • 9.2.1. Antidepressants
    • 9.2.2. Diuretics
    • 9.2.3. Pain Relievers
    • 9.2.4. Oral Contraceptives & Ovarian Suppression Agents
    • 9.2.5. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 9.3.1. Retail Pharmacies
    • 9.3.2. E-commerce
    • 9.3.3. Others
  • 9.4. Market Value Forecast, by Country, 2017 - 2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Premenstrual Syndrome Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Type, 2017 - 2031
    • 10.2.1. Antidepressants
    • 10.2.2. Diuretics
    • 10.2.3. Pain Relievers
    • 10.2.4. Oral Contraceptives & Ovarian Suppression Agents
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 10.3.1. Retail Pharmacies
    • 10.3.2. E-commerce
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Premenstrual Syndrome Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2017 - 2031
    • 11.2.1. Antidepressants
    • 11.2.2. Diuretics
    • 11.2.3. Pain Relievers
    • 11.2.4. Oral Contraceptives & Ovarian Suppression Agents
    • 11.2.5. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.3.1. Retail Pharmacies
    • 11.3.2. E-commerce
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Premenstrual Syndrome Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2017 - 2031
    • 12.2.1. Antidepressants
    • 12.2.2. Diuretics
    • 12.2.3. Pain Relievers
    • 12.2.4. Oral Contraceptives & Ovarian Suppression Agents
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.3.1. Retail Pharmacies
    • 12.3.2. E-commerce
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Premenstrual Syndrome Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2017 - 2031
    • 13.2.1. Antidepressants
    • 13.2.2. Diuretics
    • 13.2.3. Pain Relievers
    • 13.2.4. Oral Contraceptives & Ovarian Suppression Agents
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.3.1. Retail Pharmacies
    • 13.3.2. E-commerce
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis, by Company (2021)
  • 14.3. Company Profiles
    • 14.3.1. Allergan (AbbVie, Inc.)
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Bayer AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Fresenius Kabi AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Johnson & Johnson Services, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Lilly
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Mylan N.V. (Viatris, Inc.)
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Pfizer, Inc.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Teva Pharmaceutical Industries Ltd
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis